

THE EFFECT OF OVERWEIGHT AND OBESITY ON DYSLIPIDEMIA: CROSS-SECTIONAL STUDY IN HEART CENTER

**Bekbossynova M., Rysbekova A., Andosova S., Sailybaeva A.,
Daniyarova G.**

«University Medical Center» Corporate Fund, Astana, Kazakhstan

Abstract

Background. Obesity has turned into a worldwide epidemic with increasing prevalence that is associated with excess mortality and morbidity. Obesity is a risk factor for many diseases including cardiovascular disease, the leading cause of death worldwide. Aim of the study was conducted to evaluate the association of obesity with dyslipidemia and hypertension among patients with low, medium and high risk of developing cardiovascular diseases

Materials and methods. Cross-sectional study was conducted at the tertiary hospital in Astana, Kazakhstan. In total 216 participants included in this study.

Results. Student's t test was performed to elicit association between body mass index and lipid panel analysis such as cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein, where all p values found to be <0.0001. Consequently, there is a statistically significant association, and increased body mass index linked with higher lipids in the body. Obesity increases risk of atherosclerosis 2.81 times in comparison those who have a normal body mass index. Obesity increases risk of coronary angioplasty with stenting 1.91 times in comparison those who did not undergo stenting procedure.

Conclusion. Atherogenic dyslipidemia is extremely common in obesity, both in the presence and in the absence of severe insulin resistance, and is probably the main factor in the increased risk of cardiovascular diseases in these people

DOI:10.35805/BSK2024111009

Makhabbat B.

<https://orcid.org/0000-0003-2834-617X>

Aisulu S.R.

<https://orcid.org/0009-0002-5612-200X>

Saltanat A.A.

<https://orcid.org/0000-0001-7259-183X>

Aliya I.S.

<https://orcid.org/0000-0002-1489-3837>

Gulnur D.D.

<https://orcid.org/0000-0001-5876-7528>

received: 19.08.2024

accepted: 05.09.2024

Author for correspondence:

Daniyarova G.

Academic secretary "University
Medical Center" Corporate Fund,
Astana, Kazakhstan.

Postal code: 010000, Address: Kerey

and Zhanibek Khans St. 5/1,

Phone: : +77055965060,

E-mail: daniyarova.g@umc.org.kz

Conflict of interest:

The authors declare no potential
conflict of interest requiring disclosure
in this article.

Keywords:

Obesity, Dyslipidemia, Cardiovascular
risk factors, Cardiomatabolic diseases

Introduction

Obesity is widespread in the industrialized world. Body mass index (BMI) is a common non-invasive anthropometric measure used as a indicator of fat mass to assess obesity. The World Health Organization and the American Heart Association (AHA) define obesity as a BMI greater than or equal to 30 kg/m².¹⁻³

Two billion people worldwide over 18 years of age, or approximately 30% of the world's population, are overweight or obese.⁴ Studies conducted by the Kazakh Academy of Nutrition showed that the average prevalence of overweight and obesity among the adult population of Kazakhstan (15 years and older) was 29.7% in women and 33.9% in men; obesity was 25.8% in women and 15.3% in men. This means that more than half of the adult population of Kazakhstan

(55.5% of women and 49.2% of men) is overweight or obese.⁵

Overweight and obesity are responsible for more than 3.4 million deaths worldwide each year.¹ The Association for Obesity Medicine has defined obesity as: "a serious, chronic, progressive, recurrent and treatable multifactorial, neurobehavioral disease, in which increasing obesity contributes to adipose tissue dysfunction, resulting in adverse metabolic, biomechanical and psychosocial health consequences". It has been suggested that multiple mechanisms underlie the relationship between obesity and atherosclerosis, including abnormalities in lipid metabolism, insulin resistance, and inflammation.³ Adipose tissue represents the largest reservoir of free cholesterol in the body. Adipocytes and adipose tissue store the largest amount of body lipids,

including triglycerides and free cholesterol. Adipocytes and adipose tissue are endocrine and immune active. Adipocyte hypertrophy and excessive adipose tissue accumulation may contribute to the pathogenic effects of adipocytes and adipose tissue (adiposopathy), leading to abnormal levels of circulating lipids, with dyslipidemia being a major risk factor for atherosclerotic coronary heart disease.⁶ Systemic inflammation and adipokine production by adipose tissue are important mechanisms for the adverse effects of obesity on the vascular wall.³ Metabolic products, cytokines, and hormones released by adipose tissue can affect the liver by inducing changes in hepatic-derived lipoproteins, clotting factors and inflammatory factors that affect the atherogenic environment of the vessel wall. Visceral adipose tissue has access to the portal circulation and may be particularly important in this process. In addition, these same adipose tissue-derived factors have been shown to influence gene expression and cellular function of endothelial cells, arterial smooth muscle cells, and monocytes/macrophages. They represent the major cell types of the arterial wall and are key components to protect the homeostasis of the vessel wall.⁷

There are many mechanisms by which obesity may affect systemic lipid and lipoprotein metabolism. Increased production of fatty acids from adipose tissue in obesity with increased entry into the liver can lead to increased secretion of very low density lipoproteins, apolipoprotein B (apoB) and triglycerides.⁸ Other factors secreted by adipose tissue may have adverse effects on circulating lipids. For example, in a study of white men with BMI values between 22 and 35 kg/m², adiponectin was the most significant factor of plasma apoB very low density lipoprotein concentrations.⁴ Tumor necrosis factor expression is up-regulated in adipose tissue in obese patients and may have multiple effects on lipid metabolism through both paracrine effects on adipocytes and the liver.^{6,9,10}

Dyslipidemia is a widespread risk factor for coronary heart disease and an important feature of the metabolic syndrome. Obesity, especially visceral obesity, causes insulin resistance and is associated with dyslipidemia, im-

paired glucose metabolism, hypertension, which exacerbate atherosclerosis. Studies over the past 4 decades have consistently shown that the burden of dyslipidemia is very high in terms of morbidity, mortality, and medical costs. Dyslipidemia is an important risk factor for coronary heart disease (CHD), which is the leading cause of death worldwide. The World Health Organization estimates that dyslipidemia is associated with more than half of coronary heart disease cases worldwide and more than 4 million deaths per year.⁴ The American Heart Association estimates that more than 100 million Americans - one-third of all Americans - have total cholesterol levels greater than 200 mg/dL and more than 34 million American adults have levels greater than 240 mg/dL, which is considered a high level requiring treatment.¹¹ Diabetes mellitus (DM) is closely associated with dyslipidemia, with people with DM having mean LDL levels greater than 140 mg/dL.^{12,13}

Aim of the study: Obesity and dyslipidemia contribute to cardiovascular risk. This study was conducted to evaluate the association of obesity with dyslipidemia and hypertension among patients with low, medium and high risk of developing cardiovascular diseases

Materials and methods

Cross-sectional study was conducted at the tertiary hospital in Astana, Kazakhstan. In total 216 participants included in this study. Inclusion criteria for the study were:

- Patients with high and very high cardiovascular disease risk according to American college cardiovascular disease (ASCVD) risk estimator

- Age ranges from 18 to 65 years old
- Gave consent to be included for the cross-sectional study

Exclusion criteria included the patients who did not give consents to participate to the study or had following diseases:

- History or currently have cancer
- Alcoholic steatohepatitis
- Viral hepatitis
- Asthma and/or COPD
- Heart failure with ejection fraction lower than 40%.

Demographic characteristics including age, gender, nationality, comorbidities, blood analysis results, instrumental

analysis like ultrasound, computer tomography, liver ultrasound (fibroscan), echocardiography results were collected and analyzed to assess their potential influence on cardiovascular risk factors and outcomes.

Patients were divided into three groups obesity stages depending on BMI.

- Overweight (not obese), if BMI is 25.0 to 29.9
- Class 1 (low-risk) obesity, if BMI is 30.0 to 34.9
- Class 2 (moderate-risk) obesity, if BMI is 35.0 to 39.9
- Class 3 (high-risk) obesity, if BMI is equal to or greater than 40.0.

Ethical approval. Patients all signed informed consent and the study was approved by the local ethical committee (approval number № 2023/01-008 from 05.07.2024).

Statistical Analysis. For the categorical data set chi square test, and for the continuous data set student's t test, two tailed were used. P values less than 0.05 were considered to be statistically significant. Odds ratio were calculated to find risk of atherosclerosis development in regards of obesity.

Results

Out of 216 patients with high and very high risk of developing cardiovascular disease, 44.5% (n=96) to be female. Average weight for patients was 80.74 ± 15.3kg, while average body mass index and body surface area (BSA) found to be 29.03 ± 5.17kg/m² and 1.86 ± 0.2m², respectively. As mean BMI could be categorized as obese, hence we tried to break down patients on obesity stages

depending on BMI:

- Overweight (not obese), if BMI is 25.0 to 29.9
- Class 1 (low-risk) obesity, if BMI is 30.0 to 34.9
- Class 2 (moderate-risk) obesity, if BMI is 35.0 to 39.9
- Class 3 (high-risk) obesity, if BMI is equal to or greater than 40.0.

Out of 216 patients, 58 (26.8%) had normal weight, 86 (39.8%) were overweight, 54 (25%) had class 1 obesity, 12 (5.6%) had class 2 obesity and 6 (2.8%) had high risk or class 3 obesity.

190 (87.9%) had peripheral or brachiocephalic atherosclerosis. Moving to the blood analysis, mean total cholesterol level found to be 195.96 ± 43.86 mg/dL, further subdivided to low level lipoprotein (LDL) and high-density lipoprotein (HDL) which were calculated to be 132.67 ± 36.37 mg/dL and 49.18 ± 12.48. Furthermore, mean values for Non-HDL cholesterol was 146.45 ± 44.6 mg/dL and triglycerides was 143.02 ± 89.00 mg/dL. Regarding rest of the lipid panel analysis, mean Apo A was 1.29 ± 0.63 mg/dL, mean Apo B was 1.089 ± 1.26 mg/dL and LP(a) 37.47 ± 50.29 mg/dL. Among the most frequently seen comorbidities were hypertension (72.6%) and diabetes mellitus type 2 (21.2%).

Student's t test was performed to elicit association between BMI and lipid panel analysis such as cholesterol, triglycerides, LDL and HDL, where all p values found to be <0.0001. Consequently, there is a statistically significant association, and increased BMI is linked with higher lipids in the body.

	Obese n=158 (73%)	Non-obese n=58 (27%)	OR	95% CI	P value
Atherosclerosis	21	3	2.81 ^a	[0.81;9.80]	0.105
Stent	41	9	1.91 ^b	[0.86;4.22]	0.111
CABG	50	18	1,03 ^b	[0.54;1.97]	0.932
PCI	46	28	0,44 ^γ	[0.24;0.82]	0.009 *

^a - OR>1 means that the event is directly related and has a chance of occurring in the first group;
^b - OR=1 means that the odds are equal in both groups;
^γ - OR<1 means that the event is directly related and has a chance of occurring in the second group
 * P<0.05 was considered statistically significant

Table 1.
Obesity Relationship with Atherosclerosis and Interventions

Obesity increases risk of atherosclerosis 2.81 times in comparison those who have a normal BMI (Table 1).

24 (11.1%) of all patients did not have any intervention, 50 (23.2%) patients had undergone coronary angioplasty with stenting, 68 (31.5%) had coronary artery bypass grafting (CABG) surgery and lastly, 74 (34.3%) underwent both percutaneous coronary intervention (PCI) and CABG procedure.

Obese individuals are about 1.91 times more likely to have undergone stenting compared to non-obese individuals (Table 1).

Discussion

The robust body of literature extensively elucidates the well-established correlation between obesity and the progression of atherosclerosis. According to Lee *et al.*¹⁴ increased BMI is associated with the increased risk of coronary artery calcification up to 1.4 times and the tendency could be seen from the resent Gil *et al.* study¹⁵, where odds ratio for coronary artery disease development in obese patients was 1.49.^{14,15} Our results obtained from the cross-sectional study was comparable, there was 2.97 times of increased risk for obese patients to develop atherosclerotic plaques. Moreover, interestingly, Dr. Henning described in his paper from 2021, that increase in BMI above normal weight correlating with a 10% rise in risk for atherosclerosis and coronary heart disease.¹⁶

Possible mechanism that explains atherosclerosis development in the particular subset of patients could be due to the activation of adipokines/cytokines like leptin, resistin and inflammatory factor IL-6 leads to monocyte/macrophage infiltration into adipose tissue, promoting inflammation, oxidative stress, abnormal lipid metabolism, insulin resistance, and endothelial dysfunction, contributing to atherosclerosis.

To address both obesity and the associated inflammatory responses it triggers, various therapeutic avenues such as dietary adjustments, pharmaceutical interventions, and bariatric surgical procedures are explored, especially for individuals with body mass indexes surpassing 35-40 kg/m² when conventional lifestyle interventions prove ineffective. Furthermore, in obese patients grap-

pling with conditions such as hypertension, a 10-year cardiovascular disease risk exceeding 7.5%, or prediabetes/diabetes, a comprehensive treatment approach involving antihypertensive agents, lipid-lowering medications, and glucose-lowering therapies is recommended.^{3,13}

Further by focusing on the outcomes, there was at least twofold increased risk for obese patients to have either total occlusion or hemodynamically significant plaques in coronary artery (cover at least 70% of vessel diameter) further led to stenting of that vessel. Moreover, obesity is also associated with restenosis after coronary stenting, for instance Valera *et al.*¹⁷, there was 1.33 times higher risk in comparison with non-obese patients for the development of restenosis.

Potential limitations of this study include the absence of comparative analysis between the observed results on obesity-related atherosclerosis risk in healthy cohorts and the assessment of odds ratios within both subsets. Additionally, the sample size might not be sufficiently robust. Future investigations could explore the direct impact of waist-to-hip ratio or visceral fat on atherosclerosis development. Moreover, further research endeavors could delve into identifying potential genetic factors underlying atherosclerosis development, investigating whether these coincide with genes associated with obesity predisposition.

The strength of this study lies in its novelty as the first investigation to delineate the association between obesity and atherosclerosis development in Kazakhstan. Given the predominant Kazakh ethnicity of the study population, characterized by distinct dietary habits influenced by cultural traditions, it becomes imperative to contextualize these findings within a global perspective. Furthermore, the robust correlation observed between metabolic conditions such as obesity and subsequent cardiovascular disease underscores the potential impact on clinical decision-making, particularly regarding the initiation of preventive medication for hyperlipidemia in young obese patients, a matter subject to ongoing debate within the medical community.

Atherogenic dyslipidemia is extremely common in obesity, both in the

presence and in the absence of severe insulin resistance, and is probably the main factor in the increased risk of cardiovascular diseases in these people. A thorough understanding of the molecular mechanisms is crucial for further understanding the effects of obesity on lipoprotein metabolism and developing appropriate therapeutic approaches.

Limitations: This study has potential limitations. Small sample size may restrict the generalizability of the findings and increase the potential for bias. Moreover, this study describes the experience of one center and we can't generalize the findings of this research. Future research with a larger number of studies and more standardized methodologies would be beneficial to confirm and extend these findings.

What's known? Possible mechanism that explains atherosclerosis development in the particular subset of patients could be due to the activation of adipokines / cytokines like leptin, resistin and inflammatory factor IL-6 leads to monocyte / macrophage infiltration into adipose tissue, promoting inflammation, oxidative stress, abnormal lipid metabolism, insulin resistance, and endothelial dysfunction, contributing to atherosclerosis.

What's new? There was at least two-fold increased risk for obese patients to have either total occlusion or hemodynamically significant plaques in coronary artery cover at least 70% of vessel diameter further led to stenting of that vessel.

Conclusion

Atherogenic dyslipidemia is ex-

tremely common in obesity, both in the presence and in the absence of severe insulin resistance, and is probably the main factor in the increased risk of cardiovascular diseases in these people. A thorough understanding of the molecular mechanisms is crucial for further understanding the effects of obesity on lipoprotein metabolism and developing appropriate therapeutic approaches.

Acknowledgements: The authors thank Akzholova Kamila and Zhailkhan Akbota, students of Nazarbayev University school of Medicine, Bachelor of Medical science for their assistance for the design and writing of this manuscript.

Authors' Contributions: M.B.; S.A.: Study conception and design, surgeries, revising discussion section of the manuscript. A.S.; M.B.: Study design, data analysis, and interpretation, revising discussion section of the manuscript. A.R., S.A.: Data acquisition, analysis, and interpretation; surgeries, revising results section of the manuscript. G.D., A.R.: Data collection, drafting, revising results section. All authors have approved the final version of the article.

Funding: This research has been funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant No. BR21881970, Name: Development of new screening methods, to prevent early mortality and treatment of cardiovascular-diseases of atherosclerotic genesis in patients with atherosclerosis). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Afshin A, Murray CJL. Uncertainties in the GBD 2017 estimates on diet and health - Authors' reply. *Lancet*. Nov 16 2019;394(10211):1802-1803. doi:10.1016/S0140-6736(19)32629-7
2. Duncan BB, Cousin E, Naghavi M, et al. The burden of diabetes and hyperglycemia in Brazil: a global burden of disease study 2017. *Popul Health Metr*. Sep 30 2020;18(Suppl 1):9. doi:10.1186/s12963-020-00209-0
3. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. Feb 22 2022;145(8):e153-e639. doi:10.1161/CIR.0000000000001052
4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. Aug 30 2014;384(9945):766-81. doi:10.1016/S0140-6736(14)60460-8
5. Kulimbet M, Davletov K, Saliev T, et al. Assessment of hypercholes-

- terolemia prevalence and its demographic variations in the Republic of Kazakhstan. *Sci Rep.* Mar 26 2024;14(1):7182. doi:10.1038/s41598-024-57884-4
6. Richard AJ, White U, Elks CM, Stephens JM. Adipose Tissue: Physiology to Metabolic Dysfunction. In: Feingold KR, Anawalt B, Blackman MR, et al, eds. *Endotext.* 2000.
 7. Youssef A, Clark JR, Marcovina SM, Boffa MB, Koschinsky ML. Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. *Arterioscler Thromb Vasc Biol.* Mar 2022;42(3):289-304. doi:10.1161/ATVBAHA.121.317335
 8. Hillmeister P, Li K, Dai M, et al. Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany. *Front Cardiovasc Med.* 2024;11:1302152. doi:10.3389/fcvm.2024.1302152
 9. Afshin A, Lo J, Murray CJL. Dietary risk versus physical inactivity: a forced comparison with policy implications? - Authors' reply. *Lancet.* May 8 2021;397(10286):1710. doi:10.1016/S0140-6736(21)00781-9
 10. Wang DD, Li Y, Afshin A, et al. Global Improvement in Dietary Quality Could Lead to Substantial Reduction in Premature Death. *J Nutr.* Jun 1 2019;149(6):1065-1074. doi:10.1093/jn/nxz010
 11. Shangguan S, Afshin A, Shulkin M, et al. A Meta-Analysis of Food Labeling Effects on Consumer Diet Behaviors and Industry Practices. *Am J Prev Med.* Feb 2019;56(2):300-314. doi:10.1016/j.amepre.2018.09.024
 12. Richard AJ, Huckfeldt RM, Reichel E, Liang MC. Variants of Uncertain Significance: Twins With Identical Pathogenic Gene Mutations in Retinitis Punctata Albescens. *Ophthalmic Surg Lasers Imaging Retina.* Aug 2021;52(8):450-453. doi:10.3928/23258160-20210727-08
 13. Bovet P, Chioloro A, Gedeon J. Health Effects of Overweight and Obesity in 195 Countries. *N Engl J Med.* Oct 12 2017;377(15):1495-6. doi:10.1056/NEJMc1710026
 14. Lee SY, Chang HJ, Sung J, et al. The impact of obesity on subclinical coronary atherosclerosis according to the risk of cardiovascular disease. *Obesity (Silver Spring).* Jul 2014;22(7):1762-8. doi:10.1002/oby.20760
 15. Gill D, Zuber V, Dawson J, et al. Risk factors mediating the effect of body mass index and waist-to-hip ratio on cardiovascular outcomes: Mendelian randomization analysis. *Int J Obes (Lond).* Jul 2021;45(7):1428-1438. doi:10.1038/s41366-021-00807-4
 16. Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. *Am J Cardiovasc Dis.* 2021;11(4):504-529.
 17. Valera B, Sohani Z, Rana A, Poirier P, Anand SS. The ethnoepidemiology of obesity. *Can J Cardiol.* Feb 2015;31(2):131-41. doi:10.1016/j.cjca.2014.10.005